Anti-Ccl8 Therapy for Metastatic Breast Cancer


Reference #: 01150

The University of South Carolina is offering licensing opportunities for a novel therapy that slows breast cancer metastasis by interfering with Ccl8, a protein instrumental to cancer cell dissemination.

Invention Description:

The subject invention identifies the cytokine Ccl8 as a protein that is released by the stromal cells in response to signals produced by cancer cells, especially breast cancers that are triple negative (i.e Her2-, ER-, and PR-). Disrupting Ccl8 activity inhibits cancer cell migration thus providing a strategy to inhibit breast cancer metastasis.

Potential Applications:

  • Inhibiting breast cancer metastasis

Advantages and Benefits:

  1. The chemoattractive cytokine Ccl8 generates a self-sustained gradient that mediates interaction between breast cancer cells and ultimately promotes the dissemination of the cancer cells and metastasis.
  2. Blockading Ccl8 activity with neutralizing antibodies or other agents may provide a strategy for breast cancer management, especially for the inhibition of metastases.
  3. In addition to Ccl8 in the tumor, using Ccl8 in a serum may provide a biomarker for monitoring the development of breast cancers as well as the transition from estrogen-dependent to triple negative status.


Ccl8 is a cytokine produced by stromal fibroblasts in response to signals elicited by breast cancer cells, specifically those from triple-negative breast cancers. It operates as potent chemoattractant for various stromal and breast cancer cells.


Experiments have shown that breast cancers, especially the triple negatives, engage Ccl8 for their migration and metastasis. Neutralizing monoclonal antibodies for Ccl8 have been developed that could be used for the management of metastatic breast cancer.


Patent Information:
For Information, Contact:
Technology Commercialization
University of South Carolina
Hippokratis Kiaris
Eleni Farmaki
Ioulia Chatzistamou
Vimala Kaza
© 2019. All Rights Reserved. Powered by Inteum